Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Tien-Li Lee M.D. | CEO, Secretary & Director | 703.1k | -- | 1975 |
| Dr. Bryan Jones Ph.D. | Chief Operating Officer | 467.44k | -- | 1964 |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer | 503.94k | -- | 1981 |
| Mr. Nelson B. Sun M.B.A. | Chief Financial Officer | -- | -- | 1977 |
| Dr. Andreas Niethammer M.D., Ph.D. | Head of Translational Medicine | -- | -- | -- |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs | -- | -- | -- |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer | -- | -- | -- |
| Mr. Tom Bicsak Ph.D. | Head of Regulatory Affairs & Quality | -- | -- | -- |
Aardvark Therapeutics, Inc. Common Stock
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 22
Description
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Corporate Governance
Upcoming Events
March 31, 2025 at 8:10 PM UTC
Aardvark Therapeutics, Inc. Common Stock Earnings Date
Recent Events
February 10, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
January 31, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission